酪氨酸激酶抑制剂时代异基因造血细胞移植在费城染色体阳性急性淋巴细胞白血病中的作用
费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)的预后因靶向BCR::ABL1的酪氨酸激酶抑制剂(TKI)及免疫治疗而显著改善。本综述探讨异基因造血细胞移植(HCT)在当代的角色,指出其地位正依据可测量残留病(MRD)、TKI代数、分子学缓解深度与持续时间及患者因素而个体化,部分早期深度MRD阴性患者或可免于移植,但长期随访有限。
要点
- TKI联合免疫治疗使部分Ph+ ALL患者达到早期深度MRD阴性,可能无需移植。
- 移植决策应个体化,依据MRD状态、TKI代数及分子学缓解深度与持续时间。
- 移植策略需优化供者选择、预处理强度、GVHD预防及移植后TKI维持。
核心结论
- 异基因HCT不再对所有Ph+ ALL首次完全缓解患者不可或缺,其角色正转向基于MRD等因素的个体化决策。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 连续代TKI(伊马替尼至达沙替尼及近期普纳替尼)实现逐步更深更持久的分子学缓解。
- 免疫治疗尤其贝林妥欧单抗的整合使化疗节省方案成为可能,改善耐受性与疗效。
- 新数据显示部分早期深度MRD阴性患者可能无需移植即获持久缓解,但长期随访有限。
关键数值与推荐
- 移植决策参考MRD评估、TKI代数、分子学缓解深度与持续时间及患者特异因素。
临床怎么用
- 对达到早期深度MRD阴性的患者可考虑免于移植,但需权衡有限长期随访数据。
- 行移植者应优化供者选择、预处理强度、GVHD预防及移植后TKI维持以最大化GVL效应并减少毒性。
局限性
- 免于移植策略的长期随访数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), the most common subtype of adult ALL, has undergone dramatic transformation in prognosis over the past two decades. Introduction of tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 fusion protein has revolutionized frontline therapy, with successive generations of TKIs-from imatinib to dasatinib and most recently ponatinib-achieving progressively deeper and more durable molecular responses. Concurrently, the integration of immunotherapy, particularly blinatumomab, has enabled chemotherapy-sparing approaches further improving tolerability and efficacy. These advances have fundamentally challenged the historical paradigm that allogeneic hematopoietic cell transplantation (HCT) is indispensable for all Ph+ ALL patients in first complete remission. The role of allogeneic HCT is often debated and increasingly individualized, guided by measurable residual disease (MRD) assessment, TKI generation, depth and duration of molecular response, and patient-specific factors. Emerging data suggest that a subset of patients achieving early, deep MRD negativity with TKIs and immunotherapy may achieve durable remissions without transplant, though long-term follow-up remains limited. For patients proceeding to allogeneic HCT, optimization of transplant strategy-including donor selection, conditioning intensity, graft-versus-host disease prophylaxis, and posttransplant TKI maintenance-is critical to maximize graft-versus-leukemia effects while minimizing toxicity. Treatment-free remission strategies following prolonged TKI maintenance in non-transplant patients, and the integration of chimeric antigen receptor (CAR) T-cell therapy as bridge, consolidation, or salvage, represent emerging frontiers. This review critically examines the contemporary role of allogeneic HCT in Ph+ ALL and provides a framework for transplant decision-making in the contemporary era of targeted and cellular immunotherapy.
引用
- Pasic I, Lipton JH. The Role of Allogeneic Hematopoietic Cell Transplantation in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. Am J Hematol. 2026. PMID: 41987522. doi:10.1002/ajh.70330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。